AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7657737
Drug: Suprefact (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprefact (multiple daily injections)
Trial: 25162967
Drug: Low-dose metformin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose metformin (250 mg/day)
Trial: 25162967
Drug: Middle-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle-dose metformin (500 mg/day)
Trial: 25162967
Drug: High-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metformin (1500 mg/day)
Trial: 25162967
Drug: Control (untreated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (untreated with metformin)
Trial: 23486306
Drug: Standard Su‐Per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Su‐Per treatment
Trial: 23486306
Drug: Su‐Per treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Su‐Per treatment without higher stimulus at interspinous line
Trial: 19513760
Drug: Metamizole (3x1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizole (3x1000 mg)
Trial: 11752508
Drug: Corticosteroids (Cs)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (Cs) treatment
Trial: 11752508
Drug: No corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No corticosteroids (Cs) treatment
Trial: 10876967
Drug: Oral natural
RxNorm normalized name: Nature-Throid Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral natural alpha‐Interferon (OROFERONE‐IFI) at 150U tid for 8 weeks
Trial: 8880052
Drug: Deflazacort (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflazacort (12 mg, 30 mg, 60 mg)
Trial: 8880052
Drug: Prednisolone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (8 mg, 20 mg, 40 mg)
Trial: 2068049
Drug: L-acetyl carnitine
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-acetyl carnitine (1.5 g, intravenously)
Trial: 6350033
Drug: Acetylcysteine 200
RxNorm normalized name: acetylcysteine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine 200 mg b.i.d. for 6 months
Trial: 24474302
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg days 1 and 15, rifampicin 600 mg days 8-14
Trial: 24474302
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg day 1, erlotinib 450 mg day 15, rifampicin 600 mg days 8-18
Trial: 24474302
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (erlotinib 150 mg days 1 and 15)
Trial: 12356782
Drug: Glucose plus
RxNorm normalized name: DUO-CARE Glucose Plus Blood Pressure Monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose plus 0.08 g/kg body weight of Z‐trim
Trial: 12356782
Drug: Glucose plus
RxNorm normalized name: DUO-CARE Glucose Plus Blood Pressure Monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose plus 0.17 g/kg body weight of Z‐trim
Trial: 12356782
Drug: Glucose plus
RxNorm normalized name: DUO-CARE Glucose Plus Blood Pressure Monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose plus 0.33 g/kg body weight of Z‐trim
Trial: 12356782
Drug: Glucose alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose alone (1 g/kg body weight)
Trial: 9683311
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and omeprazole
Trial: 25927936
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of parenteral nutrition (PN) beyond PICU-day 7 when enteral nutrition (EN) fails
Trial: 25927936
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of parenteral nutrition (PN) within the first days to reach caloric target (control group)
Trial: 24432675
Drug: Ruji Recipe
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruji Recipe (RR) therapy
Trial: 22151676
Drug: Nitrous oxide/oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrous oxide/oxygen (50:50) self-administered until pain relief achieved (max 15 min)
Trial: 22151676
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 µg/kg) as a single dose
Trial: 16382319
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 400 IU plus calcium 1 g daily
Trial: 10886045
Drug: ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (RCM)
Trial: 10886045
Drug: bismuth subcitrate
RxNorm normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bismuth subcitrate 240 mg b.d. + amoxycillin 1000 mg b.d. + metronidazole 500 mg b.d. (BAM)
Trial: 10886045
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg o.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (OCM)
Trial: 10886045
Drug: Sensitivity to
RxNorm normalized name: Colgate Total SF Antisensitivity Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensitivity to both antibiotics
Trial: 2950915
Drug: 2% ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% ketoconazole cream and shampoo
Trial: 25555593
Drug: Wufuxinnaoqing Soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wufuxinnaoqing Soft Capsule (WSC)
Trial: 23988379
Drug: Intravenous idursulfase
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous idursulfase 0.5 mg/kg weekly for two years
Trial: 20227099
Drug: Postoperative enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative enteral infusion of the same enriched formula
Trial: 10372954
Drug: High-dose physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose physostigmine infusion (1-1.5 mg over 45-60 min)
Trial: 10372954
Drug: Chronic physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic physostigmine administration (2-12 mg/day)
Trial: 10372954
Drug: Physostigmine (cognition-enhancing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (cognition-enhancing doses)
Trial: 2053197
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg 17 beta‐oestradiol
Trial: 16125527
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone administration
Trial: 25027585
Drug: Pitavastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (2 mg daily for 12 weeks)
Trial: 25027585
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg daily for 12 weeks)
Trial: 20831683
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m2
Trial: 18619812
Drug: Cholinesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitors and atypical antipsychotics
Trial: 11220983
Drug: Milk fermented
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fermented by Lactobacillus casei (10(8) cfu/ml)
Trial: 15757856
Drug: Single high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high dose FSH (375 IU) during the early follicular phase (group A)
Trial: 15757856
Drug: 5 consecutive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 consecutive low doses FSH (75 IU/day) starting in the mid follicular phase (group B)
Trial: 15757856
Drug: Daily low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily low doses FSH (75 IU/day) during the early to late follicular phase (groups C, D, E)
Trial: 10683601
Drug: Androstenedione supplementation
RxNorm normalized name: androstenedione
DrugBank: Androstenedione (DB01536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androstenedione supplementation (200 mg daily for 2 days)
Trial: 9587536
Drug: Vaccination group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination group: 3 i.m. injections of GenHevac B followed by one booster at month 9
Trial: 9587536
Drug: Serovaccination group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serovaccination group: same vaccination schedule followed by one i.m. injection of anti‐HBs immunoglobulins (500 IU)
Trial: 8314383
Drug: Aminoglutethimide (AGT)
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (AGT) 125 mg twice daily
Trial: 8314383
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) 20 mg twice daily
Trial: 23731911
Drug: Dopamine agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonists (rotigotine or cabergoline)
Trial: 10743984
Drug: Critical pathway
RxNorm normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Critical pathway (levofloxacin treatment)
Trial: 1548352
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (10 mg/day)
Trial: 27543797
Drug: ABT-719 800
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-719 800 μg/kg
Trial: 27543797
Drug: ABT-719 1600
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-719 1600 μg/kg
Trial: 27543797
Drug: ABT-719 2100
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-719 2100 μg/kg
Trial: 21737704
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g bolus before incision, 400 mg/h infusion during surgery)
Trial: 21737704
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution infusion)
Trial: 18217908
Drug: Once-daily cyclosporine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily cyclosporine dosing (group B)
Trial: 18217908
Drug: Once-daily cyclosporine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily cyclosporine dosing with 25% dose reduction (group C)
Trial: 18217908
Drug: Twice-daily cyclosporine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily cyclosporine dosing (group A)
Trial: 18217908
Drug: Conversion to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversion to once-daily dosing
Trial: 19880675
Drug: SB-681323 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-681323 7.5 mg
Trial: 19880675
Drug: SB-681323 25
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-681323 25 mg
Trial: 19880675
Drug: Prednisolone 30
RxNorm normalized name: prednisolone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 30 mg
Trial: 11903939
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (0.1 mg x kg(‐1) in 0.2 ml x kg(‐1) saline)
Trial: 11903939
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) morphine (0.1 mg x kg(‐1) i.v. immediately after intubation, with postoperative bolus doses of 0.5 mg, 1 mg, or 1.5 mg based on weight)
Trial: 9783498
Drug: Bisoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (5 mg/d for 12 weeks, increased to 10 mg/d if DBP >= 95 mm Hg after 4 weeks)
Trial: 9783498
Drug: Bisoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (5 mg/d)
Trial: 3665118
Drug: Pre‐operative bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐operative bromocriptine therapy
Trial: 3665118
Drug: Pre‐operative bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐operative bromocriptine therapy for macroprolactinomas
Trial: 25947264
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg of oral paracetamol, 60 min before examination
Trial: 23995795
Drug: Narrow-band ultraviolet
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-band ultraviolet B (NB-UVB) treatment
Trial: 12856249
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (Botox; Allergan, Ettlingen, Germany) injections into masticatory muscles
Trial: 10566717
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (7.5 mg mixed with apple juice)
Trial: 8735681
Drug: TROPDEX (tropisetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TROPDEX (tropisetron 5 mg i.v. + dexamethasone 20 mg i.v. on day 1, followed by oral tropisetron 5 mg daily and dexamethasone 4 mg twice daily from day 2 to 6)
Trial: 8735681
Drug: METDEX (metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: METDEX (metoclopramide 1 mg kg‐1 i.v. + dexamethasone 20 mg i.v. + diphenhydramine 25 mg i.v. on day 1, followed by oral metoclopramide 20 mg 6 hourly from day 2 to 6)
Trial: 24655586
Drug: Quetiapine fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine fumarate extended release (QXR) 300 mg/day
Trial: 24655586
Drug: Escitalopram (ESC)
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram (ESC) 10 mg/day
Trial: 14976046
Drug: Prolonged rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prolonged rituximab administration (375 mg/m(2) every 2 months for 4 times)
Trial: 14976046
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment after initial response or stable disease
Trial: 14976046
Drug: Prolonged rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prolonged rituximab administration
Trial: 14976046
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment in chemotherapy-naive patients
Trial: 14976046
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment in patients responding to induction treatment
Trial: 1439632
Drug: Control (neither
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (neither treatment)
Trial: 3895024
Drug: Methicillin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methicillin (200 mg/kg divided into six i.v. doses during 24 hours starting at the induction of anesthesia)
Trial: 31776740
Drug: Low-dose CT-guided
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT-guided lung biopsy
Trial: 31776740
Drug: Standard-dose CT-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CT-guided lung biopsy
Trial: 27091236
Drug: OnabotulinumtoxinA 200
RxNorm normalized name: onabotulinumtoxinA 200 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA 200 or 300 U administered as needed for symptom control
Trial: 20100374
Drug: Probiotic yoghurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yoghurt (300 g daily for 6 weeks)
Trial: 20100374
Drug: Conventional yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional yoghurt (300 g daily for 6 weeks)
Trial: 19074086
Drug: Thrombopoietin receptor
RxNorm normalized name: Thrombopoietin receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombopoietin receptor agonists (TPO receptor agonists)
Trial: 19074086
Drug: Novel compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel compounds designed to stimulate the TPO receptor
Trial: 19074086
Drug: Adverse effects
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse effects of TPO receptor agonists
Trial: 889511
Drug: 0.125% clonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% clonidine hydrochloride solution
Trial: 889511
Drug: 0.25% clonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% clonidine hydrochloride solution
Trial: 889511
Drug: 2% pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% pilocarpine hydrochloride solution
Trial: 25167875
Drug: 2 separate
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 separate injections (0.2 + 0.2 mL/kg) of contrast medium (gadoteridol) in Group A
Trial: 25167875
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of 0.4 mL/kg of contrast medium (gadoteridol) in Group B
Trial: 16492643
Drug: Child receiving
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child receiving chemotherapy for cancer
Trial: 12094850
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg once daily (group 15qd)
Trial: 12094850
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg on alternate days (group 30qod)
Trial: 12094850
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (15 mg daily and 30 mg alternate days)
Trial: 10404055
Drug: Non-IVIG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-IVIG treatment
Trial: 7590046
Drug: Intravenous hyoscine
RxNorm normalized name: HYOSCINE HYDROBROMIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hyoscine 20 mg plus inhaled oxygen on demand
Trial: 7590046
Drug: Inhaled nitrous
RxNorm normalized name: nitrous oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitrous oxide on demand
Trial: 7590046
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water injection plus inhaled oxygen on demand (placebo)
Trial: 2082315
Drug: Oral ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketorolac 10 mg
Trial: 2082315
Drug: Oral ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketorolac 12.5 mg
Trial: 2082315
Drug: Oral ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketorolac 100 mg
Trial: 2082315
Drug: Oral ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketorolac 200 mg
Trial: 2082315
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac 90 mg
Trial: 2082315
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac 10 mg
Trial: 2082315
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac 10 mg and 30 mg
Trial: 2082315
Drug: Ketorolac doses
RxNorm normalized name: ketorolac Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac doses of 2.5 and 5 mg
Trial: 2082315
Drug: Ketorolac doses
RxNorm normalized name: ketorolac Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac doses of 10 mg or more
Trial: 2082315
Drug: Ketorolac doses
RxNorm normalized name: ketorolac Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac doses of 90 mg or more
Trial: 476711
Drug: Five-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug regimen (prednisone, cyclophosphamide, actinomycin D, vincristine, and daunorubicin)
Trial: 476711
Drug: Two-drug regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug regimen (cyclophosphamide and vincristine)
Trial: 6851562
Drug: 21-day low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 21-day low-dose combined pill
Trial: 6851562
Drug: 21-day low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 21-day low-dose combined pill followed by 7 days of iron-containing pill
Trial: 6851562
Drug: 63-day low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 63-day low-dose combined pill followed by 7 days of no pill intake
Trial: 19968839
Drug: Benznidazole (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benznidazole (two doses)
Trial: 12077585
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (methylprednisolone aceponate)